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Hepatitis C virus (HCV) infection is a serious public health problem because of its worldwide diffusion and sequelae. It is not
only a hepatotropic but also a lymphotropic agent and is responsible not only for liver injury—potentially evolving to cirrhosis
and hepatocellular carcinoma—but also for a series of sometimes severely disabling extrahepatic diseases and, in particular, B-cell
lymphoproliferative disorders. These latter range from benign, but prelymphomatous conditions, like mixed cryoglobulinemia,
to frank lymphomas. Analogously with Helicobacter pylori related lymphomagenesis, the study of the effects of viral eradication
confirmed the etiopathogenetic role of HCV and showed it is an ideal model for better understanding of themolecular mechanisms
involved. Concerning these latter, several hypotheses have been proposed over the past two decades which are not mutually
exclusive. These hypotheses have variously emphasized the important role played by sustained stimulation of the immune system
by HCV, infection of the lymphatic cells, viral proteins, chromosomal aberrations, cytokines, or microRNA molecules. In this
paper we describe the main hypotheses that have been proposed with the corresponding principal supporting data.
1. Introduction
Hepatitis C virus (HCV) infection is a major public health
problem with an estimated 3-4 million people infected each
year worldwide and about 170–200 million carriers. These
latter are at risk of developing liver cirrhosis and/or liver
cancer. More than 350,000 people die fromHCV-related liver
diseases each year. Moreover, these estimates do not take into
account the extrahepatic aspects of HCV infection.
Early after its discovery, it was shown that HCV is also a
lymphotropic virus [1]. As a consequence of the lymphatic
infection, several lymphoproliferative disorders (LPDs) have
been associated with this virus [2], including mixed
cryoglobulinemia (MC), B-cell non-Hodgkin’s lymphoma
(NHL) [3–10] and monoclonal gammopathies [11–13].
Mixed cryoglobulinemia is the most frequent and well
known LPD developing during HCV infection. Although
clinically benign, MC is a prelymphomatous disorder leading
to NHL in about 5–10% of cases. This makes MC a valuable
model for study of pathogenetic mechanisms of HCV-related
LPDs [2–14]. MC was previously interpreted as a lymphoma
in situ, being characterized by bone marrow and/or liver
infiltrates closely resembling NHL [15]. Therefore, it was
hypothesized that HCV may be involved in the pathogenesis
of NHL as well [1, 4]. This hypothesis was substantiated
by several observations, including the significantly high
prevalence of HCV infection in NHL patients in several
studies [6, 7, 10, 12, 16–18]. A lot of data are presently
available showing, in most cases, a significant association
with B-cell NHL, even with a clear south-north gradient
and involving different histopathological types of lymphoma,
the most strictly associated being the lymphoplasmacytic,
marginal zone and diffuse large B-cell lymphoma [19]. A
case-control study has shown that HCV infection increases
the risk for NHL involving the liver and major salivary
glands by about 50-fold (i.e., a risk higher than that for
hepatocellular carcinoma) and the risk for NHLs at other
sites by about 4-fold [20].
The observation of the effect of viral eradication using
antiviral agents strongly supports the etiopathogenetic link
between HCV infection and lymphomagenesis. Analogously
with what has been reported for MC, in the case of low
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Figure 1: Pathogenesis of HCV-related lymphoproliferative disorders (LPDs). Main working hypotheses and their principal interconnec-
tions.
grade B-cell lymphoma—and especially in cases of splenic
lymphoma—clinical remission following effective antiviral
therapy in HCV-associated cases has been observed [21–
23].
Interestingly, in a recent Japanese study involving about
3,000 HCV-infected patients observed during a long-term
follow-up, it was shown that the annual incidence of
lymphoma was 0.23% and the cumulative rate of lymphoma
development after 15 years was 2.6% in both the untreated
and non-responder patients with persisting infection versus
0% in treated patients achieving viral eradication, strongly
suggesting that antiviral therapy protects against the devel-
opment of lymphoma [24].
2. Mechanisms of
HCV-Related Lymphomagenesis
Several hypotheses, frequently interconnected with each
other, have been proposed in regard to the possible
mechanisms of HCV-related lymphomagenesis (Figure 1).
These include a key role played by the sustained antigenic
stimulation of the B-cell compartment, the role of viral lym-
photropism and viral proteins, chromosomal aberrations,
cytokines, and microRNAs.
2.1. The Role of Sustained Antigenic Stimulation. Sustained
HCV-driven antigenic stimulation has been suggested to
play a key role in inducing B-cell clonal expansion char-
acterizing these disorders (Figure 2). The presence in the
liver of lymphatic structures resembling lymphatic follicles
is characteristic of HCV infection. It has been suggested that
they represent an important site of B-cell clonal expansion,
especially in patients with MC, where they have been found
in almost all cases [25]. Furthermore, B lymphocytes isolated
from hepatic follicles produced rheumatoid factor (RF)
that most frequently display the WA cross-reactive idiotype,
considered to be characteristic of MC [25]. In particular,
it was observed that intrahepatic B-cell clonalities were
invariably associated with extrahepatic manifestations of
HCV infection, including high serum levels of RF activity,
cryoglobulins, monoclonal gammopathy of undetermined
significance (MGUS), and frank B-cell NHL [26]. The key
role of antigen-driven stimulation in HCV-related lympho-
proliferation was also supported by a study investigating
mutations in the V(H) and V(K) genes of the B-cell clone
inducing a frank NHL in an MC patient and producing
an IgM homologous to a protein with RF specificity. The
observation of an IgH ongoing mutation process and the
expression of an Ig antigen receptor significantly homolo-
gous to an anti-HCV protein suggested that both MC and
NHL were antigen-driven LPDs sustained by HCV [27]. The
analysis of bone marrow specimens from the same patient
taken at different times during the evolution from MC to
NHL showed a marked reduction in intraclonal diversity at
the stage of overt NHL, indicating a minor dependence of
the cells on the antigen-driven mechanism. Such a progres-
sive independence from the initial etiologic agent may be
deduced also by the effects of viral eradication in patients
with variable severity of the HCV-related LPD (see also
the following). Analogously with Helicobacter pylori-related
lymphomagenesis, it is conceivable that, during themultistep
lymphomagenic process, progressive independence from the
antigen-driven mechanism will develop, possibly due to the
occurrence of chromosomal translocations or other genetic
aberrations [14, 28] (Figure 2).
It has also been suggested that the same HCV antigens
may be involved in the induction of bothMC and lymphoma
[27, 29]. The viral antigen/s responsible for B-cell clonal
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Figure 2: HCV-related LPD pathogenesis is a multifactorial and multistep process. Current data suggest that the starting points of this
process are represented by the cooperation between a sustained and persistent stimulation—by direct or indirect action of viral particles
or proteins—and antiapoptotic mechanisms acting on B-cell compartment. A predisposing genetic background would be responsible for
the final evolution to a particular LPD (namely, MC). The progressive addition of genetic aberrations would lead to a frank neoplastic
transformation, gradually making the process less dependent on the etiologic agent.
expansion are not perfectly defined yet. However, De Re and
colleagues showed that, in patients with MC and immuno-
cytoma, the B-cell receptor (BCR) of the monoclonal,
overexpanded B-cell population, as well as the IgM-RF+
component of the cryoprecipitate, showed cross-reactivity
against HCV NS3 antigen [30].
Other studies have focused on the possible role of
proteins of theHCV envelope andmainly onHCVE2 protein
(Figure 2). It has been shown that E2 interacts with the
tetraspanin CD81, present also on the B-cell surface. This
binding has been suggested to be responsible for sustained
polyclonal B-cell activation essentially by lowering the B-cell
activation threshold [31, 32].
Data supporting the hypothesis that some HCV-
associated lymphomas could originate from B cells that
were initially activated by the HCV-E2 protein have been
provided. In fact, Quinn and coworkers showed that the
immunoglobulin from one of two HCV-associated lym-
phomas they tested bound the E2 protein in a manner iden-
tical to a bona fide human anti-E2 antibody, hypothesizing
that the B-cell activation derived from the dual binding of
E2 to a cognate BCR and to the CD81 molecule, which is a
component of a signaling complex [33].
Interestingly, the HCV-E2 protein appears to mimic
human Ig. In fact, it was observed that the N-terminal region
of E2 is antigenically and structurally similar to human
Ig variable domains and could represent a target for anti-
human IgG antibodies [34]. Consistently, the analysis of
the CDR3 sequences of the IgM-RF+ purified from the
cryoprecipitate in MC patients allowed the identification of
HCV-E2 as the antigen driving the production of IgM-RF
[35].
2.2. The Role of Viral Lymphotropism and Viral Proteins. The
potential role of viral lymphotropism in the pathogenesis
of HCV-related LPDs has been emphasized since the first
evidence of the presence of viral replication in lymphatic
cells [1] (Figure 2). The association between viral infection
of peripheral blood mononuclear cells (PBMCs) and the
presence of LPDs was initially shown in patients with MC,
where more evident infection of PBMCs in comparison
with HCV-positive patients without MC was observed [4].
HCV infection was then observed by Galli et al. in bone
marrow cells from all patients with MC versus 43% of
patients without MC [36]. After these pioneering reports,
a large amount of data correlating the presence of HCV
in the lymphatic compartment and the development of
autoimmune/lymphoproliferative disorders has been pro-
duced. In a study using the model of injection of lymphoid
cells from HCV-positive patients into SCID mice, it was
shown that the samples derived from HCV patients with
malignant LPD were characterized by positivity for HCV
replicative intermediates, stronger signals when tested for
HCV genomic sequences, and successful serial passage of
infected cells in different animals [37]. In addition, Sung
and coworkers showed the establishment of B-cell lines per-
sistently producing infectious virus from an HCV-positive
lymphoma [38].
One interesting point about the actual dimension of lym-
phocyte infection in HCV+ subjects has been provided by Pal
and coworkers who showed HCV infection in 85% of lymph
node specimens tested by in situ hybridization and HCV
replication in 50% of cases by detection of HCV replicative
intermediate [39]. Interestingly, quasispecies analysis in one
case indicated that 68% of variants circulating in serum
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were also present in lymphoid tissues, and only 40% of
serum variants were identified in liver, documenting a major
contribution of lymphoid replication to HCV viremia [39].
The existence of lymphotropic viral quasispecies has also
been demonstrated by elegant studies evaluating HCV IRES
sequence in liver and PBMC and its ability to drive viral
genome translation in different cell types [40, 41].
The M. Lai’s group, using a model of in vitro HCV
infection of B-cells, showed that the viral infection may
induce an enhanced mutation rate of immunoglobulin genes
and some oncogenes, possibly through induction of error-
prone DNA polymerase and activation-induced cytidine
deaminase (AID), suggesting that HCV may cause tumors
by a hit-and-run mechanism [42]. More recently, Ito and
coworkers observed a dramatically increased expression of
AID in the B-cells of HCV patients, suggesting that this may
be a key factor in the lymphomagenetic process mediated
by HCV [43]. Furthermore, a significantly higher expression
of several lymphomagenesis-related genes in the CD19+ of
HCV patients than in controls was also shown [43].
In regard to viral proteins, particular attention has
been focused on the HCV core protein due to previously
shown pleiotropic effects on different cell signaling pathways
modulating cell viability and proliferation [44]. Focusing on
animal models, core transgenic mice developed lymphoma
with a high frequency (80%) at ages over 20 months [45].
The core mRNA was shown in the enlarged lymph nodes
of the transgenic mice which developed lymphoma. In
another transgenic model, where the IFN signaling was
disrupted, the inducible and persistent expression of the
HCV core in the context of all structural proteins was
associated with the development of lymphoid disorders
including frank lymphoma, suggesting a synergistic action
of the viral proteins with IFN signaling impairment in
promoting lymphomagenesis [46].
More recently, the expression of the whole HCV genome,
restricted to the B-cell compartment, resulted in a high
prevalence of diffuse large B-cell lymphoma (DLBCL)(up to
29%) within 600 days after birth [47]. Interestingly, the HCV
core gene was expressed in all lymphomas. A wide analysis
of the cytokine and chemokine pattern showed elevated
levels of serum IL-2Rα in mice with lymphoma, directly
originating from lymphoma tissue [47].
The expression of the HCV core in primary B cells by
an adenoviral vector significantly inhibited B-lymphocyte
apoptosis and induced a dramatic down regulation of MHC
class II molecules. Moreover, genes associated with leukemia
and B-lymphoma were consistently up regulated by the HCV
core in this model [48].
Finally, in a study performed on both B-cell lines
expressing the HCV core protein and in primary B-cells
from patients with LPDs, it was possible to show the altered
expression of some isoforms of genes of the p53 family, the
DNp63 and DNp73, previously shown to be overexpressed in
human cancers, including lymphoma [49, 50].
Although ectopic protein expression in both in vivo and
in vitro models does not perfectly reproduce the actual
situation during chronic viral infection, the consistency
and coherence of the data accumulated until now suggest
a potential lymphomagenic effect of the core protein when
expressed as a single protein or in the context of other viral
proteins.
2.3. Chromosomal Aberrations. Interesting data are available
about the role played by chromosomal aberrations in HCV-
related LPDs. The most investigated genetic aberration was
the (14;18) translocation—t(14;18)—that was found to be
significantly associated with type II or monoclonal MC.
The presence of t(14;18) in MC was correlated with the
overexpression of the antiapoptotic bcl-2 gene in B-cells,
resulting in an imbalance of the Bcl-2/Bax ratio and abnor-
mal B-cell survival [51, 52] (Figure 2). The regression of the
expanded B-cell clones following effective antiviral treatment
and, in some relapsing patients, a new expansion of the
same clones were also shown [53]. Furthermore, a long-term
follow-up study allowed the identification of occult HCV
persistence limited to the lymphatic compartment in some
patients resulting sustained viral responders after antiviral
therapy [54, 55]. More interestingly, such a persistent occult
lymphatic infection was associated with the initial diagnosis
of MC, the persistence of some MC symptoms after therapy,
and the persistence of expanded t(14;18)+ B-cell clones
[54, 55]. The observation of the possibility, even if rare, of
a persisting MC disease in spite of complete viral eradication
suggested the existence of points of no return in the evolution
of the HCV-related lymphoproliferation.
Recently, Goldberg-Bittman et al. reported an increased
rate of aneuploidy in chronically infected HCV subjects
versus healthy controls, with values similar to an NHL
group. This observation suggests that HCV patients could
be more prone to develop a lymphatic malignancy also
because of bearing such alterations of the ploidy grade
[56]. An important contribution to understanding the set of
chromosome instability associated with HCV infection was
provided by a study of Machida and coworkers. The authors
observed a reduced expression of Rb protein—responsible
for cell cycle arrest in case of DNA abnormalities—in various
conditions including HCV-infected PBMCs isolated from
patients, hepatocyte models infected in vitro with HCV or
transfected with the viral core protein alone, and transgenic
mice expressing core protein. In fact, lower levels of Rb
could easily lead to skipping the mitosis checkpoints and
contribute to generation of polyploid cells, a condition
favoring neoplastic transformation [57].
2.4. Cytokines, Chemokines, and HCV-Related LPDs. Cytok-
ines and chemokines are essential mediators of the immune
response. A disturbance of the equilibrium between activat-
ing and repressing effects of these soluble molecules may
be responsible for several autoimmune/lymphoproliferative
disorders. Numerous reports have suggested that cytokines
and chemokines are key factors in the pathogenesis of
HCV-related LPDs. The MC model, as prelymphomatous
condition, has been widely used to investigate the cytokine
pattern characteristic of HCV-related LPDs. The role of Th1
cytokine profile (IFNγ and TNFα) and some chemokines
(MIP-1α, MIP-1β, CXCL10, and CXCR3) in the pathogenesis
of HCV-MC has been suggested by the elevated expression
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of these mediators observed in vasculitic lesions of MC
patients [58]. CXCL13 was another chemokine reported
as upregulated in MC patients [59]. This chemokine, also
known as BCA-1 (B-cell-attracting chemokine-1) or BLC
(B-lymphocyte chemoattractant), is a major regulator of B-
cell trafficking, and its expression has been found to be
significantly enhanced in microdissected samples from liver
biopsy of patients with active cutaneous vasculitis. Antonelli
and coworkers showed that serum concentrations of different
cytokines and chemokines are significantly modified in MC
patients [60] and have recently investigated the potential
role of CXCL-10 and CXCL-11 in the pathogenesis of MC
[61, 62]. In fact, high serum concentration of these soluble
factors has been shown in HCV patients with MC when
compared to patients without MC and healthy controls.
A growing body of evidence has accumulated in recent
years showing the involvement of the B-cell-activating factor
(BAFF or BLyS) in the pathogenesis of HCV-related LPDs
(Figure 2). This B-cell-specific cytokine, belonging to the
TNF-α family, is essential for B-lymphocyte development
and survival. Several reports have shown a higher BAFF
serum concentration in HCV patients than in healthy
controls and, more significantly, in HCV patients with LPDs
(for review, see [63]). The mechanisms of the enhanced
serum concentration of BAFF in HCV-LPD patients have not
been elucidated yet. A possible explanation has been recently
suggested by the analysis of the polymorphic variants of the
BAFF gene promoter. A particular allelic variant (−871 T),
reported to induce an increased transcriptional activity of the
BAFF gene [64], was significantly more frequent in patients
with HCV-related MC than in HCV patients without MC.
The genetic data were corroborated by the presence of higher
levels of the cytokine in the serum of MC patients [65, 66].
ConcerningHCV-positive subjects with NHL, Libra et al.
showed an increase in the circulating levels of IL-1β [67]. As
well, high serum osteopontin (OPN) levels were associated
with B-cell NHL and HCV infection. Interestingly, the
highest serumOPN concentrations were found amongHCV-
infected patients with concomitant type II MC with and
without B-cell NHL [68].
2.5. MicroRNAs and HCV-Related LPDs. Increasing evidence
supporting the role of microRNA (miRNA) deregulation
in the pathogenesis of chronic hepatitis C infection and
related disorders has been provided in the last years (for
review: [69]). MiRNAs are small RNA molecules (19–22-
mer noncoding RNAs) able to induce translational inhibition
of target genes by partial base complementarity to the
target mRNA 3′UTR. A liver-specific miRNA, miR-122, has
been shown to be important for HCV replication [70].
It has been shown that interferon treatment can regulate
miR-122 and other miRNA levels and that these latter
mediate—at least in part—the antiviral effects of IFN [71].
These in vitro data have been partially corroborated by
the observation of modified levels of miR-122 in patients
unresponsive to the IFN therapy [72]. A few data are still
now available concerning the involvement of miRNAs in the
pathogenesis of HCV extrahepatic disorders. An interesting
report recently analyzed the global miRNA expression profile
in HCV-related and unrelated splenic marginal zone lym-
phomas (SMZLs). By using large-scale miRNA expression
profiling analysis, Peveling-Oberhag and coworkers [73]
quantitatively evaluated the expression of 381 miRNAs in
microdissected SMZLs (HCV-positive and -negative) and
in normal splenic tissues. The difference in expression
profiles arose between SMZLs and normal spleens for 12
miRNAs, most of which were previously involved in various
mechanisms of tumor formation for both lymphomas and
other tumors. Only one miRNA, miR-26b, known to show
tumor-suppressive activity, was significantly down regulated
in HCV-positive lymphomas compared to HCV-negative
SMZLs, suggesting a possible specific mechanism by which
the virus might unfold its oncogenic potential in malignant
lymphoma.
3. Conclusions
In conclusion, as summarized in Figure 2, current data
suggest that HCV lymphomagenesis is a complex, multistep,
multifactorial process, probably based on sustained B-cell-
activation and the inhibition of B-cell apoptosis within a
background of predisposing genetic factors and evolving
through the progressive addition of genetic aberrations
which allow the process to become progressively less depen-
dent on the etiologic agent.
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